Arovella Therapeutics Ltd (ALA) - Total Liabilities
Based on the latest financial reports, Arovella Therapeutics Ltd (ALA) has total liabilities worth AU$1.33 Million AUD (≈ $940.32K USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check ALA cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Arovella Therapeutics Ltd - Total Liabilities Trend (2001–2025)
This chart illustrates how Arovella Therapeutics Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of Arovella Therapeutics Ltd.
Arovella Therapeutics Ltd Competitors by Total Liabilities
The table below lists competitors of Arovella Therapeutics Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
EITA Resources Bhd
KLSE:5208
|
Malaysia | RM161.22 Million |
|
Syntek Semiconductor Co Ltd
TWO:5302
|
Taiwan | NT$534.33 Million |
|
Classic Scenic Bhd
KLSE:7202
|
Malaysia | RM187.70 Million |
|
Diatreme Resources Ltd
AU:DRX
|
Australia | AU$2.23 Million |
|
180 Degree Capital Corp
NASDAQ:TURN
|
USA | $2.85 Million |
|
Euro Sun Mining Inc
TO:ESM
|
Canada | CA$7.09 Million |
|
CTCBIO Inc
KQ:060590
|
Korea | ₩77.43 Billion |
|
OFS Capital Corp
NASDAQ:OFS
|
USA | $191.85 Million |
Liability Composition Analysis (2001–2025)
This chart breaks down Arovella Therapeutics Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of Arovella Therapeutics Ltd to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 15.36 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 15.00 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Arovella Therapeutics Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Arovella Therapeutics Ltd (2001–2025)
The table below shows the annual total liabilities of Arovella Therapeutics Ltd from 2001 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$1.52 Million ≈ $1.08 Million |
-25.89% |
| 2024-06-30 | AU$2.06 Million ≈ $1.46 Million |
+21.63% |
| 2023-06-30 | AU$1.69 Million ≈ $1.20 Million |
+5.99% |
| 2022-06-30 | AU$1.60 Million ≈ $1.13 Million |
-6.46% |
| 2021-06-30 | AU$1.71 Million ≈ $1.21 Million |
-33.69% |
| 2020-06-30 | AU$2.57 Million ≈ $1.82 Million |
+13.02% |
| 2019-06-30 | AU$2.28 Million ≈ $1.61 Million |
-56.04% |
| 2018-06-30 | AU$5.18 Million ≈ $3.66 Million |
+63.68% |
| 2017-06-30 | AU$3.16 Million ≈ $2.24 Million |
+8.73% |
| 2016-06-30 | AU$2.91 Million ≈ $2.06 Million |
-17.35% |
| 2015-06-30 | AU$3.52 Million ≈ $2.49 Million |
-19.18% |
| 2014-06-30 | AU$4.36 Million ≈ $3.08 Million |
+7.84% |
| 2013-06-30 | AU$4.04 Million ≈ $2.86 Million |
+47.27% |
| 2012-06-30 | AU$2.74 Million ≈ $1.94 Million |
+9.98% |
| 2011-06-30 | AU$2.49 Million ≈ $1.76 Million |
-29.89% |
| 2010-06-30 | AU$3.56 Million ≈ $2.52 Million |
-54.22% |
| 2009-06-30 | AU$7.77 Million ≈ $5.50 Million |
+39.87% |
| 2008-06-30 | AU$5.55 Million ≈ $3.93 Million |
-16.74% |
| 2007-06-30 | AU$6.67 Million ≈ $4.72 Million |
+103.52% |
| 2006-06-30 | AU$3.28 Million ≈ $2.32 Million |
+1.58% |
| 2005-06-30 | AU$3.23 Million ≈ $2.28 Million |
+14.40% |
| 2004-06-30 | AU$2.82 Million ≈ $2.00 Million |
+218.60% |
| 2003-06-30 | AU$885.34K ≈ $626.43K |
+505.38% |
| 2002-06-30 | AU$146.25K ≈ $103.48K |
+3974.81% |
| 2001-06-30 | AU$3.59K ≈ $2.54K |
-- |
About Arovella Therapeutics Ltd
Arovella Therapeutics Limited, a biotechnology company, engages in the development of therapies for the treatment of cancer in Australia and internationally. It product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, … Read more